Home › Compare › VOQP vs RYLD

VOQP vs RYLD: Dividend Comparison 2026

VOQP yields 66666.67% · RYLD yields 12.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VOQP wins by $8.441837856534449e+24M in total portfolio value
10 years
VOQP
VOQP
● Live price
66666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.441837856534449e+24M
Annual income
$8,417,001,582,403,749,000,000,000,000,000.00
Full VOQP calculator →
RYLD
RYLD
● Live price
12.14%
Share price
$14.95
Annual div
$1.81
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.5K
Annual income
$2,587.35
Full RYLD calculator →

Portfolio growth — VOQP vs RYLD

📍 VOQP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVOQPRYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VOQP + RYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
VOQP pays
RYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VOQP
Annual income on $10K today (after 15% tax)
$5,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$7,154,451,345,043,187,000,000,000,000,000.00/yr
RYLD
Annual income on $10K today (after 15% tax)
$1,031.60/yr
After 10yr DRIP, annual income (after tax)
$2,199.25/yr
At 15% tax rate, VOQP beats the other by $7,154,451,345,043,187,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VOQP + RYLD for your $10,000?

VOQP: 50%RYLD: 50%
100% RYLD50/50100% VOQP
Portfolio after 10yr
$4.2209189282672247e+24M
Annual income
$4,208,500,791,201,874,400,000,000,000,000.00/yr
Blended yield
99.71%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VOQP buys
0
RYLD buys
0
No recent congressional trades found for VOQP or RYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVOQPRYLD
Forward yield66666.67% ✓12.14%
Annual dividend / share$2.00 ✓$1.81
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$8.441837856534449e+24M$44.5K ✓
Annual income after 10y$8,417,001,582,403,749,000,000,000,000,000.00 ✓$2,587.35
Total dividends collected$8.44020886744369e+24M$18.8K ✓
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: VOQP vs RYLD ($10,000, DRIP)

YearVOQP PortfolioVOQP Income/yrRYLD PortfolioRYLD Income/yrGap
1← crossover$6,677,367$6,666,666.67$11,914$1,213.65+$6.67M → VOQP
2$4,167,497,846$4,160,353,063.34$14,099$1,351.30+$4167.48M → VOQP
3$2,431,161,901,635$2,426,702,678,939.67$16,580$1,494.55+$2431161.89M → VOQP
4$1,325,636,209,022,888$1,323,034,865,788,139.00$19,384$1,642.61+$1325636209.00M → VOQP
5$675,632,775,263,916,700$674,214,344,520,262,300.00$22,535$1,794.70+$675632775263.89M → VOQP
6$321,867,481,182,444,260,000$321,144,554,112,911,900,000.00$26,063$1,950.00+$321867481182444.25M → VOQP
7$143,326,993,661,751,470,000,000$142,982,595,456,886,240,000,000.00$29,995$2,107.69+$143326993661751472.00M → VOQP
8$59,657,925,421,851,500,000,000,000$59,504,565,538,633,426,000,000,000.00$34,361$2,266.99+$59657925421851500544.00M → VOQP
9$23,211,471,150,187,795,000,000,000,000$23,147,637,169,986,416,000,000,000,000.00$39,194$2,427.12+$2.3211471150187796e+22M → VOQP
10$8,441,837,856,534,450,000,000,000,000,000$8,417,001,582,403,749,000,000,000,000,000.00$44,525$2,587.35+$8.441837856534449e+24M → VOQP

VOQP vs RYLD: Complete Analysis 2026

VOQP — Stock

VioQuest Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of clinical stage drug therapies for the treatment of oncology and infectious diseases. Its lead product includes Xyfid, which is under development for the treatment and prevention of hand-foot syndrome. The company's products also consist of VQD-002, a nucleoside analog that is in Phase I clinical trials for the treatment of cancer; and Lenocta, a small molecule inhibitor of various protein tyrosine phosphatases, which is in Phase IIa clinical trials for the treatment of melanoma, renal cell carcinoma, and other solid tumors. VioQuest Pharmaceuticals also provides chiral products, technology, and custom synthesis development services to pharmaceutical and fine chemical companies in various stages of a products' lifecycle. The company was founded in 2000 and is headquartered in Basking Ridge, New Jersey.

Full VOQP Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →
📬

Get this VOQP vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VOQP vs SCHDVOQP vs JEPIVOQP vs OVOQP vs KOVOQP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.